BHIVA guidelines on HIV and chronic hepatitis: Coinfection with HIV and hepatitis C virus infection (2005)

HIV Medicine

Volumn 6, Issue SUPPL. 2, 2005, Pages 96-106

  Nelson, Mark ^b   Matthews, Gayle ^b   Brook, M Gary ^a   Main, Janice ^b   Bateman, Paul ^b   Gilson, Richard ^b   Sabin, Caroline ^b   Wilkins, Ed ^b  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HYPERICUM PERFORATUM EXTRACT; INTERFERON; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILYBUM MARIANUM EXTRACT; STAVUDINE; ZIDOVUDINE;

ACUTE DISEASE; ANEMIA; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FIBROSIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LACTIC ACIDOSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; META ANALYSIS; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; MONOTHERAPY; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; SYSTEMATIC REVIEW; UNITED KINGDOM;

ACUTE DISEASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER DISEASES; LIVER FAILURE; PATIENT CARE TEAM; PATIENT SELECTION;

EID: 22844440701     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00300.x     Document Type: Review

References (80)

1. Public Health Laboratory Service Hepatitis C. http://www.phls.co.uk/topics_az/hepatitis_c/phlsgen_info.htm.
2. Craib KJPSC, Hogg RS, O'Shaughnessey MV et al. Evidence of sexual transmission of hepatitis C virus (HCV) in a cohort of homosexual men. 8th Conference on Retroviruses and Opportunistic Infections February 2001; 212 [Abstract 561].
3. Tedder RS, Gilson RJC, Briggs M et al. Hepatitis C virus: evidence for sexual transmission. Br Med J 1991; 302: 1299-1302.
4. Bodsworth NJ, Cunningham P, Kaldor J et al. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HTV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med 1996; 72: 118-122.
5. Communicable Disease Surveillance Centre. Increased transmission of syphilis in Brighton and Greater Manchester among men who have sex with men. Commun Dis Rep CDR Wkly 2000; 10: 383, 386.
6. Doherty L, Fenton KA, Jones J et al. Syphilis: Old problem, New Strategy. BMJ 2002; 325: 153-156.
7. Ghosn J, Pierre-François S, Thibault V et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004; 5: 303-306.
8. Sulkowski MSME, Seeff LB, Thomas DL, Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infectious Dis 2000; 30: 77-S84.
9. EASL Panel, EASL consensus statement on hepatitis C. J Hepatol 1999; 30: 956-961.
10. Browne R, Asboe D, Gilleece Y et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004; 80: 326-327.
11. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
12. Sulkowski MS, Moore RD, Mehta SH et al. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
13. De Luca A, Bugarini R, Cozzi Lepri A et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132.
14. Carlos MJ, Castilla J, López M Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004; 5: 125-131.
15. Macías J, Pineda JA, Lozano F et al. Impaired recovery of CD4 + cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 2003; 22: 675-680.
16. Chung RT, Evans SR, Yang Y et al. AIDS Clinical Trials Group 383 Study Team. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 1915-1923.
17. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C co-infected patients. Hepatology 1999; 30: 1054-1058.
18. Lesens O, Deschenes M, Steben M et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 79: 1254-1258.
19. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
20. Darby SC, Ewart D, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in the UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350: 1425-1431.
21. Eyster ME, Diamondstone LS, Lien JM et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquired Immune Deficiency Syndromes 1993; 6: 602-610.
22. Telfer P, Sabin C, Devereux H et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-561.
23. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-497.
24. Cacoub P, Geffray L, Rosenthal E et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
25. Mocroft A, Brettle R, Kirk O et al. The EuroSIDA Study Group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671.
26. Cribier B, Rey D, Schmitt C et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-1136.
27. Garcia-Samaniego J, Rodriguez M, Berenguer J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastoenterol 2001; 96: 179-183.
28. Den Brinker M, Wit F, Wertheim-van Dillen PME et al. Hepatitis B and C virus co-infection and the hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-2902.
29. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
30. Sulkowski MS, Thomas DL, Mehta SH et al. Hepatoxicity associated with nevirapine of efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
31. Sulkowski MS, Thomas D, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with Human Immunodeficiency Virus and the role of Hepatitis B or C infection. JAMA 2000; 283: 74-80.
32. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I et al. Liver toxicity due to nevirapine. AIDS 2002; 16: 290-291.
33. Fiske W et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999 [Abstract 367].
34. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitor: an immune restoration disease? AIDS 1998; 12: 2289-2293.
35. Montforte Ade A, Bugarini R, Pezzotti P et al. Low frequency of severe hepatoxicity and association with HCV coinfection in HIVpositive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-123.
36. Macías J, Castellano V, Merchante N et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C. Harmful impact of nevirapine. AIDS 2004; 18: 767-774.
37. Colin C, Lanoir D, Touzet S et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays an analysis of literature. J Vir Hep 2001; 8: 87-95.
38. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914.
39. Stramer-Susan L, Glynn-Simone A, Kleinman-Steven H et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-768.
40. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: 65-S73.
41. Berggren R. False-negative hepatitis C antibody is associated with low CD4 cell counts in HIV/HCV coinfected patients. 8th Conference on Retroviruses and Opportunistic Infections, February 2001; 212 [Abstract 5611.
42. Yee TT, Griffioen A, Sabin CA et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-851.
43. Makris M, Baglin T, Dusheiko G et al. The Transfusion Transmitted Infection Working Party of the UK Haemophilia Centre Directors Organization. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7: 339-345.
44. Jarvis LM, Watson HG, McOmish F et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infectious Dis 1994; 170: 1018-1022.
45. Smith AD, Dunk AA, Tuttle-Newhall JE et al. Hepatocellular carcinoma. Lancet 2004; 363: 898-899.
46. Soriano V, Garcia- Samaniego J. Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials 2002; 3: 351-353.
47. Puoti M, Bruno R, Castelli F et al. Comment on 'Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials 2002; 3: 419-420.
48. Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113: 40-55.
49. Child CG. The Hepatic Circulation and Portal Hypertension. Philadelphia: W.B. Saunders, 1954.
50. Imbert Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
52. Carrat F, Bani-Sadr, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848.
53. Chung R, Anderson J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
54. Garcia-Samaniego J, Soriano V Miro JM et al. The Spanish Hepatitis-HIV Consensus Panel. Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference, October 2000. HIV Clin Trials 2002; 3: 99-114.
55. Vento S, Garfano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
56. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 2002; 37 (suppl. 13): 65-68.
57. Heathcote EJ, Shiffman ML, Cooksley GE et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. NEJM 2000; 343: 1673-1680.
58. Di Martino V. Impact of HIV coinfection on the long term outcome of HCV cirrhosis. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001 [Abstract 567].
59. Soriano V, Garcia-Samaniego J, Bravo R et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 585-559.
60. Mauss S, Klinker H, Ulmer A et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4 + cell count. Infection 1998; 26: 16-19.
61. Marriott E, Navas S, del Romero J et al. Treatment with recombinant alfa-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40: 107-111.
62. Landau A, Batisse D, Vain Huyen JP et al. Efficacy and safety of combination therapy with interferon-A2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14: 839-844.
63. Dieterich DT. Combination treatment with interferon and ribavirin for hepatitis C in HIV co-infection patients (abstract 422). Program and Abstracts of the 50th Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, Texas, November 5-9, 1999 [Abstract 266].
64. Sauleda S, Esteban J, Altisent C et al. Efficacy of interferon plus ribavirin combination treatment and impact on HIV infection in hemophiliacs with chronic hepatitis C and under HAAKT. Hepatology 2000; 32: 347A [Abstract 751].
65. Landau A, Batisse D, Piketty C et al. Long-term efficacy of combination therapy with interferon alfa-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15: 2149-55.
66. Bruno R, Sacchi P, Puoti M et al. HCV chronic hepatitis in patients with HIV. clinical management issues. Am J Gastroenterol 2002; 97: 1598-1606.
67. Poynard T, McHutchinson J, Goodman Z et al. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatol 2000; 31: 211-218.
68. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med 2002; 347: 975-982.
69. Manns M, McHutchison JG, Gordon S et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001; 358: 958-965.
70. Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000; 15 (Suppl.): E156-E163.
71. Cinelli R, Di-Gennaro G, Nasti G et al. Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients. AIDS 2004; 18: 1079-1080.
72. Moreno Leonor, Quereda Carmen, Moreno Ana et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.
73. Vogt MW, Hartshorn KL, Furman PA et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235: 1376-1379.
74. Gerard Y, Maulin L, Yazdanpanah Y et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-2730.
75. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
76. Kakuda T, Brinkman K. Mitochondrial toxic effects of ribavirin. Lancet 2001; 357: 1802-1803.
77. Montes RML, Rodríguez ZM. Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients. Rev Clin Esp 2002; 202: 543-578.
78. Poynard T, Moussalli J, Ratziu V et al. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999; 3: 869-881.
79. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
80. Bhagani S. Acute hepatitis C virus (HCV) in a cohort of HIV-positive men: outcomes and response to pegylated interferon α2b and ribavirin. 10th BHIVA Conference, Cardiff, April 2004 [Abstract 020].